000141396 001__ 141396
000141396 005__ 20240229105126.0
000141396 0247_ $$2doi$$a10.1186/s12885-018-4826-3
000141396 0247_ $$2pmid$$apmid:30249195
000141396 0247_ $$2pmc$$apmc:PMC6154882
000141396 0247_ $$2altmetric$$aaltmetric:51241274
000141396 037__ $$aDKFZ-2018-01902
000141396 041__ $$aeng
000141396 082__ $$a610
000141396 1001_ $$0P:(DE-He78)eabbefb821cdb73961a5adf967330b62$$aTikk, Kaja$$b0$$eFirst author$$udkfz
000141396 245__ $$aClinical trial protocol of the ASTER trial: a double-blind, randomized, placebo-controlled phase III trial evaluating the use of acetylsalicylic acid (ASA) for enhanced early detection of colorectal neoplasms.
000141396 260__ $$aHeidelberg$$bSpringer$$c2018
000141396 3367_ $$2DRIVER$$aarticle
000141396 3367_ $$2DataCite$$aOutput Types/Journal article
000141396 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660202135_22214
000141396 3367_ $$2BibTeX$$aARTICLE
000141396 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141396 3367_ $$00$$2EndNote$$aJournal Article
000141396 520__ $$aᅟ: Immunochemical fecal occult blood tests (iFOBTs) are increasingly used for colorectal cancer (CRC) screening. In our preceding observational study, sensitivity for detecting advanced colorectal neoplasms by iFOBT was 70.8% among users of low-dose acetylsalicylic acid compared with 35.9% among non-users (p = 0.001), whereas there were only very small differences in specificity. In receiver operating characteristics (ROC) analyses, the area under the curve (AUC) was much higher for acetylsalicylic acid users than for non-users, with particularly strong differences in men (0.87 versus 0.68, p = 0.003). These findings suggested that use of acetylsalicylic acid before conduct of iFOBT might be a promising approach to improve non-invasive screening for CRC.In this randomized, double-blind, placebo-controlled trial, the diagnostic performance of two iFOBTs for detecting advanced colorectal neoplasms after a single low-dose of acetylsalicylic acid (300 mg) compared to placebo is evaluated. Acetylsalicylic acid or placebo is administered at least 5 days before a planned, study-independent colonoscopic screening in 2400 participants aged 40 to 80 years. Stool samples are obtained before and on three different days after the single dose of acetylsalicylic acid or placebo. In addition, optional blood samples are taken for future biomarker analyses. The diagnostic performance of the iFOBTs will be compared to the results of the colonoscopy as a gold standard for the diagnosis of colorectal neoplasms. Additionally, gender-specific performance of the tests and gain in diagnostic performance by test application on multiple days will be evaluated.If the findings from our preceding observational study will be confirmed in this large trial, the proposed low-risk, inexpensive intervention would considerably improve the diagnostic accuracy of iFOBTs and thus lead to enhanced early detection of colorectal neoplasms. Thus, the results of this trial may have a large public health impact.This trial was registered before recruitment of the participants in www.clinicaltrialsregister.eu on the 30th of May 2012: EudraCT No.: 2011-005603-32 and in www.drks.de on 13th of March 2012: German Clinical Trials Register DRKS-ID: DRKS00003252 .
000141396 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000141396 588__ $$aDataset connected to CrossRef, PubMed,
000141396 7001_ $$aCzock, David$$b1
000141396 7001_ $$aHaefeli, Walter E$$b2
000141396 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b3$$udkfz
000141396 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$eLast author$$udkfz
000141396 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-018-4826-3$$gVol. 18, no. 1, p. 914$$n1$$p914$$tBMC cancer$$v18$$x1471-2407$$y2018
000141396 909CO $$ooai:inrepo02.dkfz.de:141396$$pVDB
000141396 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)eabbefb821cdb73961a5adf967330b62$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000141396 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000141396 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000141396 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000141396 9141_ $$y2018
000141396 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC CANCER : 2017
000141396 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141396 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141396 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141396 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000141396 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000141396 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000141396 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review
000141396 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000141396 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000141396 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000141396 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141396 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141396 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141396 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141396 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000141396 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000141396 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000141396 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x2
000141396 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x3
000141396 980__ $$ajournal
000141396 980__ $$aVDB
000141396 980__ $$aI:(DE-He78)C070-20160331
000141396 980__ $$aI:(DE-He78)L101-20160331
000141396 980__ $$aI:(DE-He78)C060-20160331
000141396 980__ $$aI:(DE-He78)G110-20160331
000141396 980__ $$aUNRESTRICTED